The site will support CSL's growing R&D portfolio, accelerating the development of next-generation mRNA technology for vaccines "CSL's growing R&D presence in Waltham is the latest example of our ...
CSLLY's FY 2024 results were good thanks to the outperformance of the Behring segment; the company's net profit in constant currency terms grew +15% YoY to $2.91 billion, which was in line with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback